StockData

NextCure, Inc. (NXTC) stock

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.88+0.18 (+2.76%)

Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%

NextCure revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

NextCure's revenue for the twelve months ending Dec 31, 2020 was $22.38M, up 252.6% year over year. For fiscal 2020 it was $22.38M, up 252.6% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2020Dec 31, 2020$22.38M+252.6%
FY2019Dec 31, 2019$6.35M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$0-100.0%
Q1 FY2020Mar 31, 2020$22.38M+1549.1%
Q4 FY2019Dec 31, 2019$2.01M–
Q3 FY2019Sep 30, 2019$1.58M–
Q2 FY2019Jun 30, 2019$1.40M–
Q1 FY2019Mar 31, 2019$1.36M–

More NextCure figures

See a number that looks wrong?